Redx Pharma
Clinical-stage biotech developing small-molecule anti-fibrotic drugs, led by a ROCK inhibitor for Crohn's disease
Highlights
- Hiring1 open role
- New on EvolcAdded 2026-10-28
About Redx Pharma
Redx is a clinical-stage biotechnology company developing small-molecule, targeted medicines for fibrotic disease. Its lead asset, RXC008, is a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease; it has completed a Phase 1 healthy volunteer study and is preparing a Phase 2 study. Zelasudil (RXC007), a selective ROCK2 inhibitor, has reported Phase 2a data in idiopathic pulmonary fibrosis. The pipeline also includes a preclinical discoidin domain receptor (DDR) inhibitor programme and the oncology asset zamaporvint (RXC004).
The company's target customers are pharmaceutical partners and patients with fibrotic diseases. Redx has completed partnering deals with AstraZeneca, Loxo Oncology and Jazz Pharmaceuticals, and has earmarked zelasudil and zamaporvint for partnership.
Redx was founded in 2010. It is registered in Macclesfield, and its team is based at Alderley Park, Cheshire, in the UK. The company's current vacancy listing is for a Principal Translational Scientist.
Product: RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn's disease, and zelasudil (RXC007), a selective ROCK2 inhibitor for fibrotic diseases.
Jobs at Redx Pharma (1)
Redx Pharma is hiring for one role.
Principal Translational Scientist
New on Evolc
Leadership
- Lisa Anson · Chief Executive OfficerSource: company website
- Cliff Jones · Chief Technical OfficerSource: company website
- Peter Collum · Chief Financial OfficerSource: company website
- Caitlin Pearson · Head of CommunicationsSource: company website
More biotech & pharma companies
Refeyn
Mass photometry instruments and consumables for protein, antibody and viral vector analysis in research and biopharma labsSalary transparentrelationrx
AI-enabled drug discovery and development for pharmaceutical partners and patientsRelonchem
Develops and supplies own-label generic medicines for healthcare customers in the UK and international marketsNew on EvolcRenaissance Pharma
Develops an investigational anti-GD2 antibody immunotherapy for children with high-risk neuroblastomaYoung companyNew on EvolcReneuron Group
Exosome-based drug delivery platform built from engineered stem cell lines, for developers of targeted therapeuticsNew on EvolcResolution Therapeutics
Develops regenerative macrophage cell therapies for patients with inflammatory and fibrotic diseasesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- CookieScript
- Google Universal Analytics
- Hotjar
- WordPress
- jQuery
- nginx